Perspectives on Retinal Fluid Management

EP: 1.Impact of First-Line Therapy on Long-Term Outcomes in nAMD and DME

EP: 2.Choosing First-Line Therapy in nAMD or DME

EP: 3.When to Switch to More Efficacious Agents

EP: 4.Real-World Experiences With Faricimab

EP: 5.Real-World Experiences With Aflibercept 8mg

EP: 6.Efficacy and Durability: New Therapies vs Aflibercept 2mg

Now Viewing

EP: 7.Perspectives on Retinal Fluid Management

EP: 8.Perspectives on Loading Dose Recommendations for New Therapies

EP: 9.Safety Considerations for New Therapies

EP: 10.The Impact of Biosimilars in Retinal Diseases

EP: 11.The Status of Gene Therapy Development for Retinal Diseases

EP: 12.Considering Safety of Gene Therapy for Retinal Diseases

EP: 13.Role of Tyrosine Kinase Inhibitors and Gene Therapy in Retinal Diseases

EP: 14.Perspectives on the Future of Retinal Disease Management

Summary

In this segment, the discussion centers around the concept of complete fluid resolution and its significance. David Eichenbaum, MD raises the question to David Brown, MD asking whether patients who have met the extension criteria and achieved complete fluid resolution at 20 or 24 weeks are genuinely benefiting from the drug by that point. David Brown responds by referring to prior studies that had strict criteria for treatment. He notes that around 15 to 20% of patients met the criteria after three doses and were done with treatment. He emphasizes the importance of understanding how many patients, especially at the 20 or 24-week mark, are truly completely dry. He continues, expressing his preference for having criteria similar to aflibercept 8 milligrams and reports, which would provide information on how many patients achieved complete fluid resolution at extended intervals. He underscores the need for accurate data to distinguish between patients who may not need further treatment and those who would benefit from ongoing therapy based on fluid status.

This summary was AI-generated and edited for clarity.